Conference abstractPublished 18 Sep 2017
Cost-effectiveness of Niraparib, Olaparib and Rucaparib in treatment of platinum sensitive, recurrent ovarian Cancer
Texas A&M University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: To evaluate the cost-effectiveness of new ovarian cancer PARP inhibitor targeted therapy olaparib, rucaparib and nirparib as maintenance therapy for platinum sensitive, recurrent gBRCA ovarian cancer. Methods: We constructed an economic model to compare the costs and effectiveness associated with each of these treatment options based on clinical trial results from a healthcare sector perspective. Costs were measured in 2017 USD and included not only drug costs but also costs of disease monitoring and management of adverse events throughout the treatment course until disease progression. Effectiveness was measured in quality-adjusted progression-free survival years (QA-PFS) which was computed by adjusting progression free survival years (PFS) by the reported quality of life in these patients. We evaluated the incremental costeffectiveness ratio (ICER) as measured by dividing the incremental costs by the incremental effectiveness. Results: At base case, niraparib the most effective treatment option with the highest QA-PFS followed by olaprib and rucaparib. Niraparib was also associated with the highest costs followed by olaprib and rucaparib. The ICERs for niraparib compared to placebo is $260k and $155k compared to olaparib. Sensitivity analysis suggested that BRCA status impact ICERs significantly. Conclusions: PARP inhibitors significantly extends PFS in recurrent ovarian cancer patients who are sensitive to platinum based chemotherapy but are also associated with high drug costs of over 10k a month. Given a willingness to pay (WTP) between 100-150 QA-PFS, niraparib could be a cost-effective option compared to olaparib when treating patients population with at least 21% carrying BRCA mutations.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Lixian Zhong”
